Related Experiment Video
Updated: Apr 1, 2026

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
Published on: April 19, 2017
Topical treatment of basal cell carcinoma with the immune response modifier imiquimod
Dimitrios Papakostas1, Eggert Stockfleth2
1Department of Dermatology & Venerology, A Syggros Hospital, University of Athens, Medical School, 5, I. Dragoumi Str. 16121 Athens, Greece.
Imiquimod, a TLR7 agonist, is a novel immune response modifier currently widely used in the treatment of actinic keratoses (in situ squamous cell carcinoma). Imiquimod has revolutionized the treatment of field cancerization and has been approved for the treatment of superficial basal cell carcinoma with the recommendation of a 6-week treatment strategy, offering an alternative to surgery or other destructive treatment strategies.
Imiquimod, a TLR7 agonist, is a novel immune response modifier currently widely used in the treatment of actinic keratoses (in situ squamous cell carcinoma). Imiquimod has revolutionized the treatment of field cancerization and has been approved for the treatment of superficial basal cell carcinoma with the recommendation of a 6-week treatment strategy, offering an alternative to surgery or other destructive treatment strategies.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Clinical Applications of Epidermal Stem Cells
Targeted Cancer Therapies
There are several types of targeted therapies against...
Acne Infection
